With the “one-size-fits-all” approach being the norm in the psychiatric industry, HMNC Brain Health is aiming to shake this up through targeted and personalised therapies powered...
Braxia Scientific has dosed the first patients in its multi-dose psilocybin clinical trial exploring the compound’s efficacy for treatment-resistant depression (TRD).
Wesana Health and MAPS have announced the receipt of a commercial viability analysis conducted by the Boston Consulting Group (BCG) which will bring the parties closer...
Positive outcomes for the use of psilocybin therapy in conjunction with SSRIs have been reported from COMPASS Pathways’ Phase IIb trial.
As the UK sees a record number of drug overdose deaths, calls have been made for the Government to pilot Overdose Prevention Centres in a bid...
BetterLife Pharma has announced its first set of positive data showing the anti-depressant effects of an LSD derivative – 2-bromo-LSD (TD-0148A).
The new UK drug strategy is aiming to reduce drug-related crime through the largest ever increase in funding.
Cybin is to meet with the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to discuss its lead psychedelic candidate CYB003 as a treatment for Major...
Psyched Wellness presented its proprietary extract of the Amanita Muscaria mushroom, AME-1, to Health Canada representatives to discuss the evidence required in support of a Class...
Ketamine One Capital and Cognetivity Neurosciences have entered into a partnership to study and develop assessments for depression and post-traumatic stress disorder (PTSD).
